Amgen (AMGN) reported Q4 non-GAAP earnings late Wednesday of $5.31 per diluted share, up from $4.71 a year ago.
Analysts polled by FactSet expected $5.08.
Revenue for the quarter that ended Dec. 31 was $9.09 billion compared with $8.20 billion a year ago.
Analysts expected $8.88 billion.
For 2025, the biotech company is projecting non-GAAP EPS of $20.00 to $21.20 on revenue of $34.3 billion to $35.7 billion.
Analysts are looking for $20.92 and $34.62 billion, respectively.
Amgen shares were declining 2% in after-market activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。